A5056405520- Acute Myeloid Leukemia Research
- Hematopoietic Stem Cell Transplantation
- Acute Lymphoblastic Leukemia research
- Chronic Myeloid Leukemia Treatments
- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Multiple Myeloma Research and Treatments
- Retinoids in leukemia and cellular processes
- Polyomavirus and related diseases
- Neutropenia and Cancer Infections
- Histone Deacetylase Inhibitors Research
- Radiopharmaceutical Chemistry and Applications
- Hematological disorders and diagnostics
- Mesenchymal stem cell research
- Renal Transplantation Outcomes and Treatments
- Immune Cell Function and Interaction
- Childhood Cancer Survivors' Quality of Life
- Monoclonal and Polyclonal Antibodies Research
- Cytomegalovirus and herpesvirus research
- CAR-T cell therapy research
- T-cell and B-cell Immunology
- Cancer Genomics and Diagnostics
- Eosinophilic Disorders and Syndromes
- Protein Degradation and Inhibitors
University of Washington
2016-2025
Fred Hutch Cancer Center
2016-2025
University of Washington Medical Center
2014-2023
Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa
2013-2023
Cancer Research Center
2011-2022
Seattle Cancer Care Alliance
2007-2021
Seattle University
1999-2021
Executive Office of the President
2021
SWOG Cancer Research Network
2002-2017
Moffitt Cancer Center
2007-2017
Patients with acute myeloid leukemia (AML) and a FLT3 mutation have poor outcomes. We conducted phase 3 trial to determine whether the addition of midostaurin - an oral multitargeted kinase inhibitor that is active in patients standard chemotherapy would prolong overall survival this population.We screened 3277 patients, 18 59 years age, who had newly diagnosed AML for mutations. were randomly assigned receive (induction therapy daunorubicin cytarabine consolidation high-dose cytarabine)...
Abstract The 2010 and 2017 editions of the European LeukemiaNet (ELN) recommendations for diagnosis management acute myeloid leukemia (AML) in adults are widely recognized among physicians investigators. There have been major advances our understanding AML, including new knowledge about molecular pathogenesis leading to an update disease classification, technological progress genomic diagnostics assessment measurable residual disease, successful development therapeutic agents, such as FLT3,...
We treated 93 patients who had acute non-lymphoblastic leukemia in the first remission or chronic myelocytic phase (median age, 30 years) with high-dose cyclophosphamide and fractionated total-body irradiation, followed by infusion of marrow from an HLA-identical sibling. To evaluate post-grafting prophylaxis for graft versus host disease, we studied these a sequential, prospective, randomized trial that compared effect combination methotrexate cyclosporine (n = 43) alone 50). All evidence...
Over the past decade, advances have been made in care of patients undergoing transplantation. We conducted a study to determine whether these improved outcomes transplantation.We analyzed overall mortality, mortality not preceded by relapse, recurrent malignant conditions, and frequency severity major complications transplantation, including graft-versus-host disease (GVHD) hepatic, renal, pulmonary, infectious complications, among 1418 who received their first allogeneic transplants at our...
All-trans-retinoic acid induces complete remission in acute promyelocytic leukemia. However, it is not clear whether induction therapy with all-trans-retinoic superior to chemotherapy alone or maintenance treatment improves outcome.
Fludarabine is an effective treatment for chronic lymphocytic leukemia that does not respond to initial with chlorambucil. We compared the efficacy of fludarabine chlorambucil in primary leukemia.
In recipients of allogeneic hematopoietic-cell transplants, peripheral-blood cells mobilized with the use filgrastim (recombinant granulocyte colony-stimulating factor) engraft more rapidly than bone marrow. However, relative effects these techniques on rates acute and chronic graft-versus-host disease, overall survival, disease-free survival have not been determined in randomized studies.
PURPOSE: Three open-label, multicenter trials were conducted to evaluate the efficacy and safety of single-agent Mylotarg (gemtuzumab ozogamicin; CMA-676; Wyeth Laboratories, Philadelphia, PA), an antibody-targeted chemotherapy agent, in patients with CD33-positive acute myeloid leukemia (AML) untreated first relapse. PATIENTS AND METHODS: The study population comprised 142 AML relapse no history antecedent hematologic disorder a median age 61 years. All received as 2-hour intravenous...
Radiolabeled monoclonal antibodies recognizing B-lymphocyte surface antigens represent a potentially effective new therapy for lymphomas. We assessed the biodistribution, toxicity, and efficacy of anti-CD20 (B1 1F5) anti-CD37 (MB-1) labeled with iodine-131 in 43 patients B-cell lymphoma relapse.Sequential biodistribution studies were performed escalating doses antibody (0.5, 2.5, 10 mg per kilogram body weight) trace-labeled 5 to mCi 131I. The radiation absorbed by tumors normal organs...
In young adults with acute myeloid leukemia, intensive chemotherapy during the initial remission improves long-term outcome, but role of bone marrow transplantation is uncertain. We compared high-dose cytarabine autologous or allogeneic first leukemia.
Acute myeloid leukemia (AML) is the most common form of acute among adults and accounts for largest number annual deaths due to leukemias in United States. This portion NCCN Guidelines AML focuses on management provides recommendations workup, diagnostic evaluation, treatment options younger (age <60 years) older ≥60 adult patients.
Chronic myeloid leukemia can be cured by marrow transplantation from an HLA-identical sibling donor. The use of transplants unrelated donors is option for the 70 percent patients without sibling, but morbidity and mortality associated with such have been cause concern. We analyzed safety efficacy treatment chronic identified variables that predict a favorable outcome.
The period of neutropenia after autologous bone marrow transplantation results in substantial morbidity and mortality. previous phase I-II clinical trials suggest that recombinant human granulocytemacrophage colony-stimulating factor (rhGM-CSF) may accelerate neutrophil recovery thereby reduce complications patients transplantation.